CN103743832B - HPLC (High Performance Liquid Chromatography) measuring method of related substances in Dabigatran - Google Patents
HPLC (High Performance Liquid Chromatography) measuring method of related substances in Dabigatran Download PDFInfo
- Publication number
- CN103743832B CN103743832B CN201310714622.6A CN201310714622A CN103743832B CN 103743832 B CN103743832 B CN 103743832B CN 201310714622 A CN201310714622 A CN 201310714622A CN 103743832 B CN103743832 B CN 103743832B
- Authority
- CN
- China
- Prior art keywords
- dabigatran
- solution
- mobile phase
- contrast
- need testing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229960003850 dabigatran Drugs 0.000 title claims abstract description 83
- YBSJFWOBGCMAKL-UHFFFAOYSA-N dabigatran Chemical compound N=1C2=CC(C(=O)N(CCC(O)=O)C=3N=CC=CC=3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 YBSJFWOBGCMAKL-UHFFFAOYSA-N 0.000 title claims abstract description 83
- 239000000126 substance Substances 0.000 title claims abstract description 38
- 238000000034 method Methods 0.000 title claims description 6
- 238000004128 high performance liquid chromatography Methods 0.000 title description 5
- 239000000243 solution Substances 0.000 claims abstract description 100
- 238000002360 preparation method Methods 0.000 claims abstract description 32
- 238000001514 detection method Methods 0.000 claims abstract description 31
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000012535 impurity Substances 0.000 claims abstract description 19
- 229910019142 PO4 Inorganic materials 0.000 claims abstract description 14
- 239000010452 phosphate Substances 0.000 claims abstract description 14
- 230000035945 sensitivity Effects 0.000 claims abstract description 9
- 238000012360 testing method Methods 0.000 claims description 37
- 238000002347 injection Methods 0.000 claims description 12
- 239000007924 injection Substances 0.000 claims description 12
- 238000004811 liquid chromatography Methods 0.000 claims description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 10
- 230000014759 maintenance of location Effects 0.000 claims description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 8
- 239000000945 filler Substances 0.000 claims description 5
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 claims description 5
- 239000000377 silicon dioxide Substances 0.000 claims description 5
- 238000003556 assay Methods 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 238000013270 controlled release Methods 0.000 claims 2
- FGDQGIKMWOAFIK-UHFFFAOYSA-N acetonitrile;phosphoric acid Chemical compound CC#N.OP(O)(O)=O FGDQGIKMWOAFIK-UHFFFAOYSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 239000003182 parenteral nutrition solution Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 239000000047 product Substances 0.000 abstract description 9
- 239000012085 test solution Substances 0.000 abstract 3
- 239000007857 degradation product Substances 0.000 abstract 1
- 238000007865 diluting Methods 0.000 abstract 1
- 239000012071 phase Substances 0.000 description 35
- 238000000926 separation method Methods 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 239000007939 sustained release tablet Substances 0.000 description 2
- 229940123900 Direct thrombin inhibitor Drugs 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 238000010268 HPLC based assay Methods 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- WXYIONYJZVWSIJ-UHFFFAOYSA-N acetonitrile;methanol;hydrate Chemical compound O.OC.CC#N WXYIONYJZVWSIJ-UHFFFAOYSA-N 0.000 description 1
- NAYRZLVSOLIQSH-UHFFFAOYSA-N acetonitrile;methanol;phosphoric acid Chemical compound OC.CC#N.OP(O)(O)=O NAYRZLVSOLIQSH-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000005220 pharmaceutical analysis Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003868 thrombin inhibitor Substances 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
Abstract
The invention discloses a detection method of related substances in Dabigatran. The detection method adopts a diode array detector and takes an acetonitrile (flowing phase A)-phosphate solution (flowing phase B) as a flowing phase. The detection method comprises the steps of adding the flowing phase to prepare a solution containing 0.5mg of Dabigatran in 1ml by taking the Dabigatran and an appropriate quantity of related preparation containing the Dabigatran to be used as a test solution, diluting the test solution into solution containing 5mu g of Dabigatran in 1ml by using the flowing phase to be used as a contrast solution, respectively injecting a sample, wherein the sum of all impurity peak areas in a chromatogram map of the test solution is not greater than a main peak area of the contrast solution. The detection method of the Dabigatran and the related preparation containing the Dabigatran provided by the invention have the advantages that the impurities of the Dabigatran and the degradation product condition are rapidly and accurately detected, the operation is simple and direct, the sensitivity is high, and the product quality can be well controlled.
Description
Technical field
The present invention relates to the related substance detection method of a kind of dabigatran and the related preparations containing dabigatran, belong to Pharmaceutical Analysis detection field.
Background technology
Dabigatran etcxilate is direct thrombin inhibitor, have can oral, potent, without the need to features such as special Medication monitor, drug interaction are few.External, in vivo studies and clinical every research all point out dabigatran etcxilate to have good curative effect and pharmaco-kinetic properties, and potential applicability in clinical practice is optimistic, and it successfully goes on the market is an important breakthrough of anticoagulation medicine research field.Because dabigatran etcxilate likely introduces retained material and other related substance in building-up process, in storage, also likely produce catabolite, this law effectively carries out purity analysis to the dabigatran after dissociating, and this test adopts common chromatographic column (C
18chromatographic column) achieve the mensuration of dabigatran related substance fast and accurately, ensure that the quality controllable of dabigatran, have important practical significance in the quality control of synthesis and production process.Not yet retrieve the assay method of the HPLC of dabigatran related substance at present.The related substance detection method of dabigatran of the present invention and the related preparations containing dabigatran, can detect impurity and the catabolite situation of dabigatran fast and accurately.Simple to operation, highly sensitive, product quality can be controlled preferably.
Summary of the invention
The object of the present invention is to provide a kind of diode array detector that adopts to dabigatran and the assay method carrying out Related substances separation containing the related preparations of dabigatran.
The realization of Related substances separation method of the present invention comprises the following steps:
(1) chromatographic condition: detecting device adopts diode array detector, column temperature 30 DEG C, flow velocity 1.0ml/min.The mobile phase of chromatographic condition is made up of acetonitrile (mobile phase A)-phosphate solution (Mobile phase B), wherein phosphate solution (Mobile phase B), concentration range 0.005 ~ 0.015mol/L, adjustment pH scope 6.5 ~ 8.5, its optium concentration is 0.01mol/L, and optimal pH is about 7.6.Chromatogram column temperature is 30 DEG C, flow velocity 1.0ml/min.Theoretical cam curve calculates by dabigatran peak and is not less than 3000.
(2) preparation of need testing solution:
Get dabigatran or the related preparations containing dabigatran is appropriate, add the solution that mobile phase is mixed with 0.5mg/ml, as need testing solution.
(3) preparation of contrast solution:
Measure above-mentioned (2) need testing solution appropriate, add mobile phase and be diluted to the solution about containing 5 μ g in every 1ml, solution in contrast.
(4) assay method:
Get contrast solution 10 μ l injection liquid chromatography, regulate detection sensitivity, major component chromatogram peak height is made to be about 20% of full scale, get need testing solution 10 μ l injection liquid chromatography again, record chromatogram is to 2 times of dabigatran main peak retention time, if any impurity peaks in need testing solution chromatogram, measure each impurity peak area and, the peak area (see accompanying drawing 1, accompanying drawing 2) of main peak in contrast solution must not be greater than.
The related substance detection method of dabigatran of the present invention and the related preparations containing dabigatran, the preparation of need testing solution in above-mentioned (2): for meeting the needs of need testing solution detectable concentration, get dabigatran appropriate, being mixed with concentration with mobile phase is the solution of every 1ml containing 0.5mg, as need testing solution.Be diluted to the solution of a series of variable concentrations more respectively with mobile phase, respectively sample introduction 10 μ l, make it to produce the signal that main peak is baseline noise three times.Through test, detectability is 0.5ng(S/N >=3), if calculate with concentration 0.5mg/ml during Related substances separation, its limit of detection is 0.1%.
The related substance detection method of dabigatran of the present invention and the related preparations containing dabigatran, the preparation of contrast solution in above-mentioned (3): precision measures above-mentioned need testing solution 1ml, put in 100ml measuring bottle, add mobile phase and dissolve and be diluted to scale, solution in contrast.When this contrast solution concentration range is in 1 ~ 8 μ g/ml, peak area and concentration are good linear relationship, and its linearly dependent coefficient is that 0.9997(is shown in accompanying drawing 3).
Dabigatran of the present invention and the related substance detection method of related preparations containing dabigatran, its related substance detects in high-efficient liquid phase chromatogram, occurs if any impurity peaks, measure each impurity peak area and, the main peak area (1%) of contrast solution should be greater than.
Dabigatran of the present invention and the related substance detection method of related preparations containing dabigatran, be applicable to variously need to carry out the dabigatran of related substance detection and the related preparations containing dabigatran, as dabigatran etcxilate sheet.
The present invention's good effect is compared with the prior art:
1, the present invention uses diode array detector to carry out related substance detection to this product, establish a kind of effective ways of evaluation chromatographic peak purity of quicklook: the purity that can judge chromatographic peak intuitively, and judge the position that there is Interference Peaks, whole spectral informations of " at stream " can be obtained, obtain the absorption spectrum of chromatographic component fast, the UV-visible detector that diode array detector is more general, it is qualitative that advantage is to rely on the retention time of chromatogram to carry out, and the spectral information that can provide according to it carries out qualitative, substantially increase confidence level qualitatively.And effectively improve its detection sensitivity.
2, the related substance detection method of dabigatran of the present invention and the related preparations containing dabigatran, can detect impurity and the catabolite situation of dabigatran fast and accurately.Product quality can be controlled preferably.
3, the present invention is applicable to the dabigatran of various formulation and the related preparations containing dabigatran, as dabigatran sheet.
4, detection method is accurate, simple to operation, and favorable reproducibility is highly sensitive, fully can meet the requirement that Related substances separation measures with decomposition product, the special impurities preferably in Quality control, guarantee product quality, practical at work.
Embodiment
embodiment one:
1, chromatographic condition and system suitability:
1.1, the selection of chromatographic condition:
Instrument: Shimadzu: LC-20AT, SPD-M20A, SIL-20A, DGU-20A5, its optimum column temperature 30 DEG C, flow velocity 1.0ml/min.Liquid-phase chromatographic column octadecylsilane chemically bonded silica is filling agent (250mm × 4.6mm, 5 μm), with reference to pertinent literature binding tests concrete condition, successively select the multiple condition such as methanol-water, acetonitrile-water, methanol-acetonitrile-water, methanol-acetonitrile-phosphate solution, finally determine that mobile phase is made up of acetonitrile (mobile phase A)-phosphate solution (Mobile phase B), wherein phosphate solution (Mobile phase B), concentration range 0.005 ~ 0.015mmol/L, adjustment pH scope 6.5 ~ 8.5, its optium concentration is 0.01 mol/L, and optimal pH is about 7.6.Sample size 10 μ l.
Under this chromatographic condition, dabigatran main peak retention time is moderate, and peak shape is better.
1.2, to get dabigatran reference substance appropriate for sensitivity determination, being mixed with concentration with mobile phase is the solution of every 1ml containing 0.5mg, be diluted to the solution of a series of variable concentrations more respectively with mobile phase, respectively sample introduction 10 μ l, make it to produce the signal that main peak is baseline noise three times.Through test, detectability is 0.5ng(S/N >=3), if calculate with concentration 0.5mg/ml during Related substances separation, its limit of detection is 0.1%.Result proves, the method is highly sensitive, fully can meet the requirement that Related substances separation measures.
1.3, stability of solution is got with a need testing solution, respectively at 0,2,6,10,15 hour respectively sample introduction measure, its main peak peak area and determination of related substances result basicly stable in 15 hours.
Above test findings shows, the method is easy to be sensitive, favorable reproducibility, can detect preferably the quality of dabigatran in sample preferably.
2, the preparation of need testing solution:
Get dabigatran or the related preparations containing dabigatran is appropriate, add the solution that mobile phase is mixed with 0.5mg/ml, as need testing solution.
3, the preparation of contrast solution:
Measure above-mentioned (2) need testing solution appropriate, add mobile phase and be diluted to the solution about containing 5 μ g in every 1ml, solution in contrast.
4, the detection of dabigatran and the related preparations related substance containing dabigatran:
Get contrast solution 10 μ l injection liquid chromatography, regulate detection sensitivity, major component chromatogram peak height is made to be about 20% of full scale, get need testing solution 10 μ l injection liquid chromatography again, record chromatogram is to 2 times of dabigatran main peak retention time, if any impurity peaks in need testing solution chromatogram, measure each impurity peak area and, the peak area of main peak in contrast solution must not be greater than.
the mensuration of embodiment two, dabigatran etcxilate sheet related substance
Get this product 20, accurately weighed, porphyrize, precision takes in right amount (being about equivalent to dabigatran 5mg), adds mobile phase and is mixed with the solution containing 0.5mg in every 1ml, filter, get filtrate as need testing solution.Precision measures in right amount, adds mobile phase and is diluted to the solution about containing 5 μ g in every 1ml, solution in contrast.Under following selected chromatographic condition: diode array detector (Shimadzu: LC-20AT, SPD-M20A, SIL-20A, DGU-20A5), be filling agent with octadecylsilane chemically bonded silica, mobile phase is made up of acetonitrile (mobile phase A)-phosphate solution (Mobile phase B), wherein phosphate solution (Mobile phase B), concentration range 0.005 ~ 0.015mol/L, adjustment pH scope 6.5 ~ 8.5, its optium concentration is 0.01mol/L, and optimal pH is about 7.6.Chromatogram column temperature is 30 DEG C, flow velocity 1.0ml/min.
Theoretical cam curve should be not less than 3000. by the calculating of dabigatran peak and get contrast solution 10 μ l injection liquid chromatography, regulate detection sensitivity, make that contrast solution main peak is high is about 20% of full scale, get each 10 μ l of need testing solution again, injection liquid chromatography respectively, record chromatogram is to 2 times of major component peak retention time.If any impurity peaks in need testing solution chromatogram, measure each impurity peak area and, the main peak area of contrast solution must not be greater than.
Table 1. dabigatran etcxilate sheet determination of related substances result
First second batch of lot number the 3rd batch |
Related substance (%) 0.18 0.17 0.21 |
the mensuration of embodiment three, dabigatran etcxilate capsule related substance
Get this product content appropriate, porphyrize, precision takes fine powder (being about equivalent to dabigatran 5mg), adds mobile phase and is mixed with the solution containing 0.5mg in every 1ml, filter, get filtrate as need testing solution.Precision measures in right amount, adds mobile phase and is diluted to the solution about containing 5 μ g in every 1ml, solution in contrast.Under following selected chromatographic condition: diode array detector (Shimadzu: LC-20AT, SPD-M20A, SIL-20A, DGU-20A5), be filling agent with octadecylsilane chemically bonded silica, mobile phase is made up of acetonitrile (mobile phase A)-phosphate solution (Mobile phase B), wherein phosphate solution (Mobile phase B), concentration range 0.005 ~ 0.015mol/L, adjustment pH scope 6.5 ~ 8.5, its optium concentration is 0.01mol/L, and optimal pH is about 7.6.Chromatogram column temperature is 30 DEG C, flow velocity 1.0ml/min.
Theoretical cam curve should be not less than 3000. by the calculating of dabigatran peak and get contrast solution 10 μ l injection liquid chromatography, regulate detection sensitivity, make that contrast solution main peak is high is about 20% of full scale, get each 10 μ l of need testing solution again, injection liquid chromatography respectively, record chromatogram is to 2 times of major component peak retention time.If any impurity peaks in need testing solution chromatogram, measure each impurity peak area and, the main peak area of contrast solution must not be greater than.
Table 2. dabigatran etcxilate capsule determination of related substances result
First second batch of lot number the 3rd batch |
Related substance (%) 0.22 0.15 0.13 |
the mensuration of embodiment four, dabigatran etcxilate sustained release tablets related substance
Get this product appropriate, porphyrize, precision takes fine powder (being about equivalent to dabigatran 5mg), adds mobile phase and is mixed with the solution containing 0.5mg in every 1ml, filter, get filtrate as need testing solution.Precision measures in right amount, adds mobile phase and is diluted to the solution about containing 5 μ g in every 1ml, solution in contrast.Under following selected chromatographic condition: diode array detector (Shimadzu: LC-20AT, SPD-M20A, SIL-20A, DGU-20A5), be filling agent with octadecylsilane chemically bonded silica, mobile phase is made up of acetonitrile (mobile phase A)-phosphate solution (Mobile phase B), wherein phosphate solution (Mobile phase B), concentration range 0.005 ~ 0.015mol/L, adjustment pH scope 6.5 ~ 8.5, its optium concentration is 0.01mol/L, and optimal pH is about 7.6.Chromatogram column temperature is 30 DEG C, flow velocity 1.0ml/min.
Theoretical cam curve should be not less than 3000. by the calculating of dabigatran peak and get contrast solution 10 μ l injection liquid chromatography, regulate detection sensitivity, make that contrast solution main peak is high is about 20% of full scale, get each 10 μ l of need testing solution again, injection liquid chromatography respectively, record chromatogram is to 2 times of major component peak retention time.If any impurity peaks in need testing solution chromatogram, measure each impurity peak area and, the main peak area of contrast solution must not be greater than.
Table 3. dabigatran etcxilate sustained release tablets determination of related substances result
First second batch of lot number the 3rd batch |
Related substance (%) 0.18 0.15 0.23 |
accompanying drawing illustrates:
Fig. 1: the HPLC collection of illustrative plates of contrast solution
Fig. 2: the HPLC collection of illustrative plates of need testing solution
Fig. 3: dabigatran l.o.i linear relationship chart.
Claims (4)
1. a related substance detection method for dabigatran and the related preparations containing dabigatran, is characterized in that detecting device adopts diode array detector; The mobile phase of chromatographic condition is made up of mobile phase A acetonitrile and Mobile phase B phosphate solution, wherein the concentration range of phosphate solution is 0.005 ~ 0.015mol/L, adjustment pH scope 6.5 ~ 8.5, and chromatogram column temperature is 30 DEG C, flow velocity 1.0ml/min, gradient elution program is as following table:
, detection method comprises the following steps:
(1) chromatographic condition:
This product adopts octadecylsilane chemically bonded silica to be filling agent, and with acetonitrile-phosphate solution for mobile phase, flow velocity is 1.0ml/min, and theoretical cam curve calculates by dabigatran and is not less than 3000;
(2) preparation of need testing solution:
Get dabigatran or the related preparations containing dabigatran is appropriate, add the solution that mobile phase is mixed with 0.5mg/ml, as need testing solution;
(3) preparation of contrast solution:
Measure above-mentioned (2) need testing solution appropriate, add mobile phase and be diluted to the solution about containing 5 μ g in every 1ml, solution in contrast;
(4) assay method:
Get contrast solution 10 μ l injection liquid chromatography, regulate detection sensitivity, major component chromatogram peak height is made to be about 20% of full scale, get need testing solution 10 μ l injection liquid chromatography again, record chromatogram is to 2 times of dabigatran main peak retention time, if any impurity peaks in need testing solution chromatogram, measure each impurity peak area and, the peak area of main peak in contrast solution must not be greater than.
2. the related substance detection method of dabigatran according to claim 1 and the related preparations containing dabigatran, is characterized in that: the optium concentration of Mobile phase B phosphate solution is 0.01mol/L, and optimal pH is 7.6.
3. the detection method of dabigatran according to claim 1 and the related substance containing dabigatran related preparations, it is characterized in that: the wherein preparation of (3) contrast solution: get dabigatran related preparations appropriate, add the solution that mobile phase is mixed with 0.5mg/ml, as need testing solution; Precision measures test sample 1ml again, puts in 100ml measuring bottle, adds mobile phase and dissolves and be diluted to scale, solution in contrast.
4. according to the detection method of described dabigatran arbitrary in claims 1 to 3 and the related substance containing dabigatran related preparations, it is characterized in that: the method be applicable to various need to carry out related substance detection dabigatran or related preparations containing dabigatran, as tablet, capsule, granule, parenteral solution, controlled release ease up the compound preparation of controlled release and various dabigatran.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310714622.6A CN103743832B (en) | 2013-12-23 | 2013-12-23 | HPLC (High Performance Liquid Chromatography) measuring method of related substances in Dabigatran |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310714622.6A CN103743832B (en) | 2013-12-23 | 2013-12-23 | HPLC (High Performance Liquid Chromatography) measuring method of related substances in Dabigatran |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103743832A CN103743832A (en) | 2014-04-23 |
CN103743832B true CN103743832B (en) | 2015-04-22 |
Family
ID=50500870
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310714622.6A Expired - Fee Related CN103743832B (en) | 2013-12-23 | 2013-12-23 | HPLC (High Performance Liquid Chromatography) measuring method of related substances in Dabigatran |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103743832B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109975448B (en) * | 2017-12-28 | 2022-05-20 | 成都倍特药业股份有限公司 | Method for detecting related substances or/and content of dabigatran etexilate mesylate or preparation thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103304539A (en) * | 2012-03-07 | 2013-09-18 | 天津药物研究院 | Dabigatran etexilate malate, and preparation method and application thereof |
-
2013
- 2013-12-23 CN CN201310714622.6A patent/CN103743832B/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103304539A (en) * | 2012-03-07 | 2013-09-18 | 天津药物研究院 | Dabigatran etexilate malate, and preparation method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN103743832A (en) | 2014-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104914185A (en) | HPLC method for measuring related substances in Favipiravir | |
CN106706785A (en) | Method for detecting related substances in irbesartan hydrochlorothiazide tablets by adopting high performance liquid chromatography | |
CN103926335B (en) | The high-efficient liquid phase chromatogram process measuring method of related substance in a kind of Dapoxetine hydrochloride | |
CN103344733A (en) | High performance liquid chromatographic separation detection method for bortezomib enantiomers | |
CN103063769B (en) | Quality detecting method for mecobalamine capsule | |
CN103926332B (en) | A kind of Ultra Performance Liquid Chromatography method of uridine, guanosine and adenosine content in Simultaneously test pinellia tuber extract | |
CN103115969A (en) | Method for determining residual quantities of organic solvents in temozolomide hexyl ester | |
CN102375033A (en) | High performance liquid chromatographic analysis method of bendamustine hydrochloride and its related substances | |
CN101038280B (en) | HPLC-ELSD measuring method for correlated matter in memantine hydrochloride | |
CN105021728A (en) | Method for determination of contents of impurities in cefuroxime axetil raw material medicine by high performance liquid chromatography | |
CN103364502B (en) | High performance liquid chromatography (HPLC) determination method for related substances in difluprednate | |
CN106053625A (en) | Method utilizing HPLC to measure higenamine hydrochloride related substances | |
CN103743832B (en) | HPLC (High Performance Liquid Chromatography) measuring method of related substances in Dabigatran | |
CN104237407A (en) | Method for detecting releasing rate of amantadine hydrochloride sustained release tablets | |
CN101458235B (en) | Matrine liquid chromatography measuring method | |
CN102841169B (en) | Method for measuring calcium levofolinate-related substances by using high performance liquid chromatography gradient method | |
CN102608231A (en) | Method for determining content of vitamin C in vitamin C effervescent tablets by HPLC (high performance liquid chromatography) | |
CN103134886A (en) | Method for analytical separation sodium ibandronate and impurities thereof by utilizing high performance liquid chromatography (HPLC) | |
CN110514759A (en) | The detection method of azido compound in a kind of candesartan Cilexetil | |
CN103163228A (en) | Efficient liquid phase analysis method for hydroxyfasudil and preparation thereof | |
CN103353494B (en) | HPLC (high performance liquid chromatography) detection method of related substances in almotriptan malate | |
CN105911193A (en) | Method for detecting relevant substances in piperacillin sodium and sulbactam sodium for injection | |
CN104374855B (en) | The method of woodruff thuja acid and 10-deacetyl asperulosidic thuja acid content in HPLC Simultaneously test Noni juice | |
CN105675754A (en) | Method for measuring linagliptin enantiomer content by high-performance liquid chromatography | |
CN107966498B (en) | Method for detecting solvent residue in Idelalis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150422 |
|
CF01 | Termination of patent right due to non-payment of annual fee |